



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/768,781 | 01/25/2001 | Gennady Merkulov | CL001057-CIP | 3929 |

25748 7590 02/24/2004

CELERA GENOMICS CORP.
ATTN: WAYNE MONTGOMERY, VICE PRES, INTEL PROPERTY
45 WEST GUDE DRIVE
C2-4#20
ROCKVILLE, MD 20850

EXAMINER

BASI, NIRMAL SINGH

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1646

DATE MAILED: 02/24/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/768,781

Applicant(s)

MERKULOV ET AL.

Examiner

Nirmal S. Basi

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 December 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 4,8,9 and 24-29 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 4,8,9 and 24-29 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on 03 December 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>7/15/03</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. The Amendment filed 12/03/03 has been entered.
2. The drawings were received on 12/03/03. These drawings are approved by the Examiner.
3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action (6/3/03).
4. Response to Applicants Arguments for claim rejections under 35 USC § 101 and 35 USC § 112, 1st paragraph

Claims 4, 8-9 and 24-29 remain rejected under 35 U.S.C. 101 and 35 U.S.C. 112, first paragraph, for reasons of record (6/3/03). Applicant argues molecules of the present invention have uses within the commercial market place in the drug development cycle, since they encode previously unidentified members of important pharmaceutical targets. Applicant also argues, the present invention provides sufficient knowledge and information that is beneficial to the public, provides sufficient guidance for researchers to use the claimed subject matter to develop disease treatments and/ or diagnostics, the disclosure of a new member of this family advances the art and augments the capabilities of biomedical researchers to combat illness, the claimed invention is a valuable drug target and has apparent commercial utilities such as for screening potential drug compounds, producing antibodies, developing hybridization probes and primers. Applicant further argues a tissue specific pattern of expression of claimed protein/nucleic acid are commercially useful for developing therapeutic

Art Unit: 1646

agents for treating diseases affecting these tissues. Further applicant argues that membership to the family of transporter proteins is sufficient to support for a substantial, specific use even though each member may play a somewhat different role in cellular responses. Applicant arguments have been fully considered but not found persuasive.

Neither the specification nor the art of record disclose the protein of SEQ ID NO:2 encoded by or the polynucleotide of SEQ ID NO:1 and 3, useful to identify drugs that affect said protein and modulate its activity. Similarly, neither the specification nor the art of record disclose any instances where disorders associated with claimed nucleic acid dysfunction can be effected by interfering with the activity of the protein of SEQ ID NO:2 or polynucleotide of SEQ ID NO:1 and 3. Thus the corresponding asserted utilities are essentially methods of treating unspecified, undisclosed diseases or conditions, which does not define a "real world" context of use. Treating an unspecified, undisclosed disease or condition would require or constitute carrying out further research to identify or reasonably confirm a "real world" context of use. Since neither the specification nor the art of record disclose any activities or properties that would constitute a "real world" context of use for the claimed nucleic acid, vector comprising said nucleic acid or cells comprising said vector, further experimentation is necessary to attribute a utility to the claimed invention. See *Brenner v. Manson*, 383 U.S. 519, 535-36, 148 USPQ 689, 696 (1966) (noting that "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing", and stated, in context of the utility

Art Unit: 1646

requirement, that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.").

The peptides and proteins of instant invention are claimed to have functional domain of membrane transport protein XK. Applicant argues XK proteins may play a role in sodium-dependent transport of neutral amino acids and oligopeptides. The role played by claimed invention is not disclosed not the molecule transported by claimed transporter. Claimed invention is claimed to be useful in the development of human therapeutics and diagnostic compositions and methods. Further, the specification discloses the nucleic acid molecules of present invention are useful for probes, primers, chemical intermediates, and in biological assays. The utilities disclosed in the specification are based on methods using claimed nucleic acid or the encoded polypeptide as a target for diagnosis and treatment in transporter-mediated and related disorders and for drug-screening methods using transporter peptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The specification discloses ion channels and transporter proteins regulate many different cell proliferation, differentiation and signaling pathways and mediate a wide variety of cellular functions. The claimed nucleic acid is expressed in a wide variety of tissues. The specification does not disclose which transporter protein or ion channel protein is encoded by claimed nucleic acid, nor any disease states affected by its dysfunction. Further, the ligand affected or transported by the protein of SEQ ID NO:2 is not disclosed. There is no clear showing that the polynucleotide of SEQ ID NO:1 encodes a specific transport protein. Further, the

Art Unit: 1646

ligand affected or transported by the protein encoded by SEQ ID NO:1 is not disclosed. There is no clear showing that the polynucleotide of SEQ ID NO:1 encodes a XK protein. The specification fails to disclose the relationship of the protein encoded by the polynucleotide of SEQ ID NO:1 to a particular transporter protein.

Neither the specification nor the art of record disclose the protein of SEQ ID NO:2 or the polynucleotide of SEQ ID NO:1 and 3 useful to identify drugs that affect said protein and modulate its activity. Similarly, neither the specification nor the art of record disclose any instances where disorders associated with claimed nucleic acid dysfunction can be effected by interfering with the activity of the protein of SEQ ID NO:2 or polynucleotide of SEQ ID NO: 1 and 3. Thus the corresponding asserted utilities are essentially methods of treating unspecified, undisclosed diseases or conditions, which does not define a "real world" context of use. Treating an unspecified, undisclosed disease or condition would require or constitute carrying out further research to identify or reasonably confirm a "real world" context of use. Since neither the specification nor the art of record disclose any activities or properties that would constitute a "real world" context of use for the claimed nucleic acid, vector comprising said nucleic acid or cells comprising said vector, further experimentation is necessary to attribute a utility to the claimed invention. See *Brenner v. Manson*, 383 U.S. 519, 535-36, 148 USPQ 689, 696 (1966) (noting that "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing", and stated, in context of the utility

Art Unit: 1646

requirement, that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.").

Based on the specification it can be speculated that the nucleic acid of present invention encodes a protein, which may be a transporter protein, which in turn may be related to the XK subfamily. The specification provides no data that the claimed nucleic acid expresses a functional transporter protein, its relationship to a particular chloride channel subfamily, any ligands that activate, or the expression of claimed invention in a functional system that transports chloride ions. Specific regions of the transporter protein required for activity are not disclosed.

Although the claimed polynucleotide of claimed invention is expressed in wide variety of tissues there is no clear nexus between the expression of claimed polynucleotide and a disease state or dysfunction. There is no nexus relating methods of using the transporter protein/nucleic acid as a target for diagnosis and treatment in transporter-mediated disorders. In light of the specification the skilled artisan can speculate that the claimed nucleic acid encodes a protein and may belong to the transporter superfamily. However, no disclosure is provided within the instant specification on what specific function claimed transporter possesses, or how to specifically assay for such, ligands that bind, promoters that activate, nor are any disease states disclosed that are directly related to claimed invention dysfunction.

The specification discloses that the claimed polynucleotides are useful as tools for drug discovery, screening assays and the diagnosis of disease. For a

Art Unit: 1646

utility to be "well-established" it must be specific, substantial and credible. All nucleic acids and genes and their encoded polypeptides may in some combination be useful in drug discovery, screening assays and the diagnosis of disease. However, the particulars of testing with SEQ ID NO:1-3 are not disclosed in the instant specification. The disease states, screening assays or ligands that bind to the protein encoded by claimed nucleic acid of instant invention are not identified. Therefore, this is a utility, which would apply to virtually every member of a general class of materials, such as any collection of proteins or DNA, but is only potential with respect to SEQ ID NO:1-3. Because of this, such a utility is not specific and does not constitute a "well-established" utility. Further, because any potential diagnostic utility is not yet known and has not yet been disclosed, the utility is not substantial because it is not currently available in practical form. Moreover, use of the claimed polynucleotide in an array for screening is only useful in the sense that the information that is gained from the array is dependent on the pattern derived from the array, and says nothing with regard to each individual member of the array. Again, this is a utility, which would apply to virtually every member of a general class of materials, such as any collection of proteins or DNA. Even if the expression of Applicants' individual polynucleotide is affected by a test compound in an array for drug screening, the specification does not disclose any specific and substantial interpretation for the result, and none is known in the art. Given this consideration, the individually claimed polynucleotide has no "well-established" use. The artisan is required to perform further experimentation on the claimed

Art Unit: 1646

material itself in order to determine to what "use" any expression information regarding this nucleic acid could be put.

With regard to diagnosis of disease, in order for a polynucleotide or protein to be useful, as asserted, for diagnosis of a disease, there must be a well established or disclosed correlation or relationship between the claimed polynucleotide and a disease or disorder. The presence of a polynucleotide in a wide variety of tissue is not sufficient for establishing a utility in diagnosis of disease in the absence of some information regarding a correlative or causal relationship between the expression of the claimed cDNA or protein and the disease. If a molecule is to be used as a surrogate for a disease state, some disease state must be identified in some way with the molecule. There must be some expression pattern that would allow the claimed polynucleotide to be used in a diagnostic manner. The claimed polynucleotide is expressed in normal tissues and diseased tissues. Evidence of a differential expression might serve as a basis for use of the claimed polynucleotide as a diagnostic for a disease. However, in the absence of a clear disclosed relationship between the claimed polynucleotide or the protein that is encoded thereby and any disease or disorder and the lack of any correlation between the claimed polynucleotide or the encoded protein with any known disease or disorder, any information obtained from an expression profile would only serve as the basis for further research on the observation itself. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object

Art Unit: 1646

of use-testing.” *Brenner*, 148 USPQ at 696. The disclosure does not present a substantial utility that would support the requirement of 35 U.S.C. §101.

The specification fails to disclose sufficient properties of the protein and/or polynucleotide (SEQ ID NO:1-3) to support an inference of utility. Assignment to this family does not support an inference of utility because the members are not known to share a common utility. There are some protein families for which assignment of a new protein in that family would convey a specific, substantial and credible utility to that protein. For example, some families of enzymes such as proteases, ligases and telomerases share activities due to the particular specific biochemical characteristics of the members of the protein family such as non-specific substrate requirements, that are reasonably imputed to isolated compositions of any member of the family.

Without some common biological activity for the family members, a new member would not have a specific and substantial utility when relying only on the fact that it has structural similarity to the other family members. The members of the family have different biological activities which may be related to tissue distribution but there is no evidence that the claimed compounds share any one of diverse number of activities. That is, no activity is known to be common to all members. To argue that all the members can be used for screening/testing for drugs, and diagnosis of disease, is to argue a general, nonspecific utility that would apply to virtually every member of the family, contrary to the evidence. Further, any compound could be considered as a regulator or modulator of tissue in that any compound, if administered in the proper amount, will stimulate or

Art Unit: 1646

inhibit tissue. For example, salt, ethanol, and water are all compounds which will kill cells if administered in a great enough amount, and which would stimulate cells from which these compounds had been withheld, therefore, they could be considered regulators or modulators of tissue. However, use of these compounds for the modulation of tissue would not be considered a specific and substantial utility unless there was some disclosure of, for example, a specific and particular combination of compound/composition and application of such in some particular environment of use.

Without knowing a biological significance of the claimed the polynucleotides or the polypeptide encoded thereby, one of ordinary skill in the art would not know how to use the claimed invention in its currently available form in a credible "real world" manner based on the diversity of biological activities possessed by ionotropic receptors. Contrast *Brenner*, 148 USPQ at 694 (despite similarity with adjacent homologue, there was insufficient likelihood that the steroid would have similar tumor-inhibiting characteristics), with *In re Folkers*, 145 USPQ 390, 393 (CCPA 1965) (some uses can be immediately inferred from a recital of certain properties) or *In re Brana*, 34 USPQ 1436, 1441 (Fed. Cir. 1995) (evidence of success in structurally similar compounds is relevant in determining whether one skilled in the art would believe an asserted utility; here, an implicit assertion of a tumor target was sufficiently specific to satisfy the threshold utility requirement).

The utility of claimed transporter cannot be implicated solely from homology to known channels because the art does not provide teaching stating

Art Unit: 1646

that all members of family must have the same effects, the same ligands and be involved in the same disease states. The claimed invention of instant invention is considered by the examiner to be possibly a member of the ion channel family. The art shows it requires more than the disclosed homology to assign a function to an orphan protein.

The specification asserts that the use of the claimed invention for drug discovery, screening assays and the diagnosis of disease are substantial utilities. The question at issue is whether or not the broad general assertion that the claimed nucleic acids might be used for *some* diagnostic application in the absence of a disclosure of *which* diagnostic application would be considered to be an assertion of a specific, substantial, and credible utility. For reasons set forth above the disclosure satisfies none of the three criteria See *In re Kirk*, 153 USPQ 48, 53 (CCPA 1967) (quoting the Board of Patent Appeals, 'We do not believe that it was the intention of the statutes to require the Patent Office, the courts, or the public to play the sort of guessing game that might be involved if an applicant could satisfy the requirements of the statutes by indicating the usefulness of a claimed compound in terms of possible use so general as to be meaningless and then, after his research or that of his competitors has definitely ascertained an actual use for the compound, adducing evidence intended to show that a particular specific use would have been obvious to men skilled in the particular art to which this use relates.')

Even though, instant invention may have functional domain of an XK protein a reasonable correlation to its function and activity has not been established.

Art Unit: 1646

The present rejection under § 101 follows *Brenner v. Manson*, as set forth above. In that case, the absence of a demonstrated specific utility for the claimed steroid compound was not ameliorated by the existence of a demonstrated general utility for the class. Unlike *Fujikawa v. Wattanasin*, where there were pharmaceutically acceptable in vitro results, here, there is nothing other than relatively low levels of sequence homology to a broad and diverse family of proteins having distinct modes of activity, and no disclosed common mode of action. Further a rejection under § 112, first paragraph, may be affirmed on the same basis as a lack of utility rejection under § 101. See, e.g., *In re Swartz*, 56 USPQ2d 1703 (Fed. Cir. 2000); *In re Kirk*, 153 USPQ 48 (CCPA 1967).

Therefore, for reasons set forth above, the inventions of instant invention remain rejected for lack of utility.

5. Claims 4, 8-9 and 24-29 remain rejected under 35 U.S.C. 112, first paragraph for reasons of record (6/3/03). Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. Since neither the specification nor the art of record disclose any activities or properties that would constitute a "real world" context of use for the claimed nucleic acid, vector containing said nucleic acid, host cell comprising said vector, and method of producing polypeptide encoded by said nucleic acid, further experimentation is necessary to attribute a utility to the claimed nucleic acid molecule

Art Unit: 1646

(polynucleotide consisting of SEQ ID NO:1 and SEQ ID NO:3) encoding receptor polypeptides of SEQ ID NO:2.

Specifically, since the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention so that it would operate as intended without undue experimentation.

No claim is allowed.

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nirmal S. Basi whose telephone number is 571-272-0868. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax

Art Unit: 1646

phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Nirmal S. Basi
Art Unit 1646
2/22/04

W/S

Michael D. Pak
MICHAEL PAK
PRIMARY EXAMINER